# Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors

> **NCT06684327** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 100 (estimated)

## Conditions studied

- Paget Disease, Extramammary
- Rhabdomyosarcoma
- Testicular Cancer
- Penile Cancer
- Urachal Cancer

## Interventions

- **DRUG:** Albumin-paclitaxel Injection

## Key facts

- **NCT ID:** NCT06684327
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-30
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06684327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06684327, "Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06684327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*